Navigation Links
Delcath Systems, Inc. Completes Phase III Study Enrollment
Date:10/21/2009

NEW YORK, Oct. 21 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that its pivotal Phase III Metastatic Melanoma Trial has met its goal of 92 patients and is fully enrolled. This clinical study is evaluating the Delcath PHP System(TM) for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver.

With the achievement of complete enrollment, the company remains on-track for a FDA submission of its Delcath PHP System(TM) with melphalan in 2010. Trial enrollment will continue for the near-term to include additional patients that have begun the evaluation process and may be eligible to participate.

"We always expected to see the greatest enrollment activity in the second half of the study period as positive word about the Delcath PHP System spread and attracted new patients to the study," said Eamonn Hobbs, President and CEO of Delcath Systems. "We are delighted to have completed enrollment on-plan, and to continue the extremely positive momentum created over the last six months. We have achieved several key, strategic milestones, including the successful review of our Phase III safety data, orphan drug designation for doxorubicin for the treatment of hepatocellular carcinoma, and the additions of David McDonald as Chief Financial Officer and Dr. Krishna Kandarpa as Chief Medical Officer and EVP of Research and Development. We also executed on our plans to build our own manufacturing facility, which we will continue to develop as we focus for the remainder of the year on preparation for our FDA submission, commercialization and international licensing."

About the Phase
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
10. Guided Delivery Systems, Inc. Successfully Treats First Patient with Mitral Regurgitation
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), a ... products for the treatment of central nervous system disorders, ... Vanda,s President and CEO, will deliver a corporate presentation ... New York City on Thursday, June 4, ... presentation at the Jefferies Global Healthcare Conference will be ...
(Date:6/2/2015)... International plc (NASDAQ: ENDP ) (TSX: ENL) (the ... an underwritten public offering of $1.75 billion of ordinary ... are to be sold by Endo. ... the Offering an option, exercisable for a period of ... supplement, to purchase an additional $262.5 million of ordinary ...
(Date:6/2/2015)... STATESVILLE, N.C. , June 2, 2015 ... its Board of Directors declared a quarterly cash dividend ... 26, 2015 to stockholders of record at the close ... About Kewaunee Scientific Founded in 1906, Kewaunee ... design, manufacture, and installation of laboratory, healthcare, and technical ...
Breaking Medicine Technology:Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 2Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 3Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 4
... BOSTON, Dec. 29, 2011  Solos Endoscopy, Inc. (OTCPK: SNDY) ... continued growth in 2012 through the development and sales ... treatment and management of medical conditions. In 2011, Solos ... approximately $300,000 in debt for the Company. The signed ...
... Dec. 29, 2011 Janssen Research & Development, LLC (JRD) ... Application (sNDA) to the U.S. Food and Drug Administration (FDA) ... an oral anticoagulant, to reduce the risk of (thrombotic) cardiovascular ... The filing is supported by data from the pivotal Phase ...
Cached Medicine Technology:Solos Endoscopy, Inc. is Primed for Growth in 2012 2Solos Endoscopy, Inc. is Primed for Growth in 2012 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 2Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 3Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 4Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 5Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 6Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 7Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 8Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 9Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 10Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 11
(Date:6/2/2015)... Aidan Booth And Steve Clayton's ... yesterday, and has since received rave reviews from ... Tiffany Hendricks has weighed in with her opinion ... on her website HonestyFirstReviews.com. , "These days the ... looking to hone their business skills has gotten ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Food Lion ... its sixth annual “Thriller on the Griller” events, starting ... and South Carolina locations. Each event will raise funds ... to restoring a sense of self, restoring the family ... our military families. , Through these events, Food ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 MEDIA ... Wallace, 571-319-9594 (cell) , Email: ewallace(at)mentalhealthamerica(dot)net , Breaking ... New Mental Health Legislation at MHA Annual Conference ... What: Rep. Murphy to address the Mental Health ... the long-awaited updated version of the Helping Families ...
(Date:6/2/2015)... April 8th, 2015, saw the transformation ... Entertainment’s “RockNRolla Movie Awards” EcoLuxe Lounge, a daylong event, ... of the world’s top providers of ecologically sound and ... by Debbie Durkin, Los Angeles’ leading producer of sustainable ... is a premier red carpet event that makes appearances ...
(Date:6/2/2015)... 2015 On March 19th, 2015, LiveToBeSober.org ... the Hall of Legends at Detroit’s Ford Field. Hosted ... Herman Moore, the goal of the conference was to ... society, highlight the benefits of effective professional rehabilitation programs. ... the options that are available to them in regards ...
Breaking Medicine News(10 mins):Health News:100K Factory - Review of Aidan Booth and Steve Clayton's New IM System Published 2Health News:Food Lion to Launch “Thriller on the Griller” Events to Benefit Military Families through Hope For The Warriors® 2Health News:Food Lion to Launch “Thriller on the Griller” Events to Benefit Military Families through Hope For The Warriors® 3Health News:Congressman Tim Murphy to Unveil Details of New Mental Health Legislation at MHA Annual Conference Thursday 2Health News:Choices Recovery South Bend Discusses Addiction With Rising Hollywood Star Ben Stillwell 2Health News:Rehabilitation Facility Graduate Shares Her Story at "Fighting Addiction Together" Conference 2
... teachers and students prefer enhanced sex education programs//, they ... UK schools. When teen pregnancy is taken into consideration, ... officials said. The study, which was conducted by the ... Medical Journal, covered about 25 secondary schools. ...
... of Parliament tuesday that she would resign if the ... by March 2007. ,Her comment was ... select committee who were apprehensive about the NHS's half-year ... NHS trusts are forecasting deficits. The deficits are expected ...
... over the effects of drinking too much alcohol on their ... While alcohol-related deaths have doubled in last 15 years, just ... last 3 months, worried about the effects of over drinking ... exercise and too much stress – says Legal & General. ...
... type of salmonella bacteria.It is usually found in eggs infected ... bacteria is now found more often in chicken meat. Tests ... increase of salmonella enteritidis on chicken meat., ,Salmonella is ... year with an annual death toll of about 600 in ...
... play an important role in how insects develop from ... model for congestive heart failure// to be effective in ... rhythms, according to UC Davis research published in the ... Academy of Sciences. ,The research, led by cardiologist ...
... includes products like insulin, sugar-free food and healthcare books, ... 'D' Lounge has been set up by Way-to-Health, a ... ,"'D' Lounge offers a complete range of products ... biscuits, jams and honey. Sugar-free toothpaste is also available ...
Cached Medicine News:Health News:Insect Protein Effective for Treating Heart Enlargement, Arrythmias 2
Angled for temporal approach. Solid 14 mm blades. Dull finish....
Open 11 mm blades. Polished finish....
Open 10 mm blades. Dull finish....
Angled for temporal approach. Open 14 mm rounded blades for patient comfort. Dull finish....
Medicine Products: